The Innovative Targets Portfolio: Basic Life Sciences Research to Novel Therapies, through a Portfolio of Small Molecule Translational Projects

Lead Research Organisation: University of Dundee

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding.  It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.

Publications

10 25 50
 
Description Diamond XChem screen for FabA
Amount £20,000 (GBP)
Organisation Diamond Light Source 
Sector Private
Country United Kingdom
Start 01/2018 
End 03/2018
 
Description Eastbio PhD studentship
Amount £140,000 (GBP)
Organisation East of Scotland BioScience (EastBio) 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2016 
End 08/2020
 
Description drug discovery funding
Amount £14,860 (GBP)
Organisation Tenovus Cancer Care 
Department Tenovus Scotland
Sector Charity/Non Profit
Country United Kingdom
Start 04/2017 
 
Description Open innovation (AZ-OGA) 
Organisation AstraZeneca
Country United Kingdom 
Sector Private 
PI Contribution The University of Dundee will use their OGA assay platform to screen the AZ compound libraries in order to identify new classes of OGA inhibitor. If suitable compounds are identified The University of Dundee will conduct structural biology, Medicinal chemistry and associated drug discovery activities to develop the hit compounds toward in vivo leads.
Collaborator Contribution AZ will provide access to AZ screening facilities and will provide access to proprietary compound libraries.
Impact Project in early stages and no outputs generated to date.
Start Year 2016
 
Description Research Collaboration Agreement with AstraZeneca 
Organisation AstraZeneca
Country United Kingdom 
Sector Private 
PI Contribution Dundee presented a drug target that had been screened in the DDU in 2013. Confirmed hits were optimised but not further developable. We discussed with AZ a desire to screen against a different library to look for new start points
Collaborator Contribution AZ have provided diversity and fragment libraries to Dundee
Impact A new diversity screen will be completed q1 2017
Start Year 2016